Literature DB >> 9633524

Differential binding characteristics and cellular inhibition by soluble VEGF receptors 1 and 2.

W Roeckl1, D Hecht, H Sztajer, J Waltenberger, A Yayon, H A Weich.   

Abstract

The FLT-1 and KDR genes encode transmembrane tyrosine kinases which function as high-affinity receptors for vascular endothelial growth factor (VEGF). We have used the baculovirus system to express the extracellular parts of the FLT-1 receptor and KDR receptor in soluble form (sFLT-1 and sKDR), for in vitro binding and competition assays. Here, we show that the binding of VEGF165 to sKDR but not sFLT-1 is dependent on heparin, regardless of whether VEGF165 or sKDR is immobilized. Further, only sFLT-1 acts as a receptor antagonist in solution and sKDR can neither compete with the binding of VEGF165 to human endothelial cells carrying both receptors nor block VEGF165 induced mitogenicity. Soluble KDR only partially inhibits cell migration even at high concentrations, in contrast to sFLT which can almost completely block (82%) VEGF-induced cell proliferation and migration. Taken together these results show that the two soluble VEGF receptor proteins, sFLT-1 and sKDR, despite binding the same ligand, behave very differently when immobilized with regard to their dependence on heparin for VEGF binding. In solution their respective ability to function as receptor antagonists is also strikingly different, possibly a reflection of their different dependency on heparin.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9633524     DOI: 10.1006/excr.1998.4039

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  28 in total

1.  Soluble VEGF receptor 1 promotes endothelial injury in children and adolescents with lupus nephritis.

Authors:  Monika Edelbauer; Sudhir Kshirsagar; Magdalena Riedl; Heiko Billing; Burkhard Tönshoff; Dieter Haffner; Jörg Dötsch; Gottfried Wechselberger; Lutz T Weber; Elisabeth Steichen-Gersdorf
Journal:  Pediatr Nephrol       Date:  2011-12-07       Impact factor: 3.714

2.  GM-CSF induces expression of soluble VEGF receptor-1 from human monocytes and inhibits angiogenesis in mice.

Authors:  Tim D Eubank; Ryan Roberts; Michelle Galloway; Yijie Wang; David E Cohn; Clay B Marsh
Journal:  Immunity       Date:  2004-12       Impact factor: 31.745

3.  Serum vascular endothelial growth factor receptor-2 and adropin levels in age-related macular degeneration.

Authors:  Nurgül Örnek; Kemal Örnek; Süleyman Aydin; Musa Yilmaz; Yaşar Ölmez
Journal:  Int J Ophthalmol       Date:  2016-04-18       Impact factor: 1.779

Review 4.  Sequential drug delivery to modulate macrophage behavior and enhance implant integration.

Authors:  Erin M O'Brien; Gregory E Risser; Kara L Spiller
Journal:  Adv Drug Deliv Rev       Date:  2019-05-16       Impact factor: 15.470

5.  A single-nucleotide polymorphism in a half-binding site creates p53 and estrogen receptor control of vascular endothelial growth factor receptor 1.

Authors:  Daniel Menendez; Alberto Inga; Joyce Snipe; Oliver Krysiak; Gilbert Schönfelder; Michael A Resnick
Journal:  Mol Cell Biol       Date:  2007-01-22       Impact factor: 4.272

6.  The role of RPE cell-associated VEGF₁₈₉ in choroidal endothelial cell transmigration across the RPE.

Authors:  Haibo Wang; Pete Geisen; Erika S Wittchen; Bradley King; Keith Burridge; Patricia A D'Amore; M Elizabeth Hartnett
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-02-01       Impact factor: 4.799

7.  Immune cells regulate VEGF signalling via release of VEGF and antagonistic soluble VEGF receptor-1.

Authors:  T Hoeres; M Wilhelm; M Smetak; E Holzmann; G Schulze-Tanzil; J Birkmann
Journal:  Clin Exp Immunol       Date:  2018-01-04       Impact factor: 4.330

8.  Soluble and membranous vascular endothelial growth factor receptor-2 in pregnancies complicated by pre-eclampsia.

Authors:  Richa Tripathi; Gayatri Rath; Ranju Ralhan; Sunita Saxena; Sudha Salhan
Journal:  Yonsei Med J       Date:  2009-10-21       Impact factor: 2.759

9.  Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth.

Authors:  Romulo J C Albuquerque; Takahiko Hayashi; Won Gil Cho; Mark E Kleinman; Sami Dridi; Atsunobu Takeda; Judit Z Baffi; Kiyoshi Yamada; Hiroki Kaneko; Martha G Green; Joe Chappell; Jörg Wilting; Herbert A Weich; Satoru Yamagami; Shiro Amano; Nobuhisa Mizuki; Jonathan S Alexander; Martha L Peterson; Rolf A Brekken; Masanori Hirashima; Seema Capoor; Tomohiko Usui; Balamurali K Ambati; Jayakrishna Ambati
Journal:  Nat Med       Date:  2009-08-09       Impact factor: 53.440

10.  A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases.

Authors:  M Meyer; M Clauss; A Lepple-Wienhues; J Waltenberger; H G Augustin; M Ziche; C Lanz; M Büttner; H J Rziha; C Dehio
Journal:  EMBO J       Date:  1999-01-15       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.